ADPTAdaptive Biotechnologies Corporation
$25.51+48% 1Y
$25.51
$12.4152 weeks$29.86
Is the price fair?
What ADPT's price assumes
Adaptive Biotechnologies Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 13.2× revenue.
13.2
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 28.5
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 12.1
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 28.5
- EV / EBIToperating margin −12%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 12.1
- Market capitalisation159.6 million shares, counted Jul 31, 2026
- $4.07B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #12 of 21 by RyuScore